We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 20, 2021

Health-Related Quality of Life With Pembrolizumab vs Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181
J. Clin. Oncol 2021 Nov 03;[EPub Ahead of Print], A Adenis, AS Kulkarni, GC Girotto, C de la Fouchardiere, H Senellart, HWM van Laarhoven, W Mansoor, R Al-Rajabi, J Norquist, M Amonkar, S Suryawanshi, P Bhagia, JP Metges

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading